Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Eplerenone 25 Mg Tabs 100 Unit Dose By Greenstone Ltd.

Image 0 of Eplerenone 25 Mg Tabs 100 Unit Dose By Greenstone Ltd.Image 1 of Eplerenone 25 Mg Tabs 100 Unit Dose By Greenstone Ltd.

Eplerenone 25 Mg Tabs 100 Unit Dose By Greenstone Ltd.

Call for Price

Eplerenone 25 Mg Tabs 100 Unit Dose By Greenstone Ltd. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD4055919/RXB10024355
Size : 100
Selling UoM : EA
NDC: 59762-1710-01
UPC Barcode : 359762171016
Supplier: 0050002034 GREENSTONE LIMITED
Supplier Material : 6911
Generic Code : 051036 EPLERENONE ORAL TABLET 25 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : GRX Generic RX

Have a question?

  Call for Price

Product Description.:

G, 25mg
tablet , film-coated , yellow , diamond diamond
BiconvexDebossed

INSPRA contains eplerenone, a blocker of aldosterone binding at the mineralocorticoid receptor. Eplerenone is an odorless, white to off-white crystalline powder. It is very slightly soluble in water, with its solubility essentially pH-independent. The octanol/water partition coefficient of eplerenone is approximately 7.1 at pH 7.0.

INSPRA for oral administration contains 25 mg or 50 mg of eplerenone and the following inactive ingredients: lactose, microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, talc, magnesium stearate, titanium dioxide, polyethylene glycol, polysorbate 80, and iron oxide yellow and iron oxide red.

INDICATIONS
Patient Selection Considerations

Serum potassium levels should be measured before initiating INSPRA therapy, and INSPRA should not be prescribed if serum potassium is > 5.5 mEq/L. [See CONTRAINDICATIONS].
Congestive Heart Failure Post-Myocardial Infarction

INSPRA is indicated to improve survival of stable patients with left ventricular (LV) systolic dysfunction (ejection fraction 40%) and clinical evidence of congestive heart failure (CHF) after an acute myocardial infarction (MI).
Hypertension

INSPRA is indicated for the treatment of hypertension. INSPRA may be used alone or in combination with other antihypertensive agents.

SIDE EFFECTS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

* Hyperkalemia [See WARNINGS AND PRECAUTIONS]

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials Experience
Congestive Heart Failure Post-Myocardial Infarction

In EPHESUS, safety was evaluated in 3307 patients treated with INSPRA and 3301 placebo-treated patients. The overall incidence of adverse events reported with INSPRA (78.9%) was similar to placebo (79.5%). Adverse events occurred at a similar rate regardless of age, gender, or race. Patients discontinued treatment due to an adverse event at similar rates in either treatment group (4.4% INSPRA vs. 4.3% placebo), with the most common reasons for discontinuation being hyperkalemia, myocardial infarction, and abnormal renal function.